The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
<iframe src="https://statesidedaily.com/embed/cluster/f0719a7da3e9b2997f19f36beeb57f962e5e01c3" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned"></iframe>
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
